Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients

Area of Science:

• Pediatric Hematology Oncology
• Transplantation Medicine
• Biostatistics

Background:

• Quantifying hematopoietic cell transplantation (HCT)-related mortality in children is complex.
• The HCT-specific comorbidity index (HCT-CI) is validated in adults but not yet in pediatric populations.
• Accurate risk stratification is crucial for optimizing pediatric HCT outcomes.

Purpose of the Study:

• To validate the predictive utility of the HCT-specific comorbidity index (HCT-CI) for mortality in pediatric patients undergoing allogeneic HCT.
• To assess the correlation between pretransplantation HCT-CI scores and nonrelapse mortality (NRM) and overall survival (OS).
• To establish the HCT-CI as a reliable tool for risk assessment and counseling in pediatric HCT.

Main Methods:

• Retrospective cohort study of 252 pediatric patients undergoing their first allogeneic HCT.
• Prospective scoring of pretransplantation comorbidities using the HCT-specific comorbidity index (HCT-CI).
• Analysis of 1-year cumulative incidence of NRM and overall survival (OS) based on HCT-CI scores (0, 1-2, 3+).

Main Results:

• Increasing HCT-CI scores correlated with significantly higher 1-year NRM (10% to 28%, P<.01) and lower OS (88% to 62%, P<.01).
• Multivariate analysis revealed that HCT-CI scores of 3+ were associated with a 4.5-fold increased risk of NRM (P<.01) compared to score 0.
• HCT-CI scores of 1-2 showed a trend towards increased NRM risk (RR 1.5, P=.48).

Conclusions:

• The HCT-specific comorbidity index (HCT-CI) is a validated and useful tool for predicting nonrelapse mortality and overall survival in pediatric HCT.
• The HCT-CI facilitates risk assessment, patient counseling, and the development of targeted therapies for high-risk pediatric HCT populations.
• This validation supports the routine use of the HCT-CI in pediatric HCT settings to improve patient care and outcomes.